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of cavoatrial tumors with hypothermic cir-
culatory arrest. We previously reported on
a similar series of 12 patients operated on
between 1990 and 1995,2 and we take this
opportunity to outline several aspects not
described in the previously published re-
view.
Two of our patients died (multiorgan
failure). Both showed a preoperative ejec-
tion fraction less than 30% and no cardiac
condition amenable to surgical correction.
Left ventricular dysfunction may therefore
represent a relative contraindication for op-
eration (at least, for prolonged circulatory
support and deep hypothermic techniques).
We had a substantially higher rate of post-
operative complications. A serum creati-
nine level rise of more than 2 mg/dL was
observed in 5 of 12 cases, although this
condition was present before the operation
in 3 of the 5, and dialysis was never re-
quired. Transient jaundice occurred in 9 of
12 patients. It can be speculated that tumor
thrombus may impair hepatic venous drain-
age, and thus hepatic “functional reserve,”
despite normal results of preoperative liver
function tests.
From a technical standpoint, we agree
that hypothermic circulatory arrest is the
optimal approach. We performed an atri-
otomy before cavotomy in all cases to
gain open distal access and reduce em-
bolic risks. This preceded en bloc tumor
resection through the inferior vena cava
(IVC). If the thrombus is unusually ad-
herent to the IVC, infiltration should be
suspected and a more aggressive resec-
tion considered; in our experience, 1 such
patient died of local tumor recurrence. In
addition, if circulatory support is not
used, specific maneuvers may be hazard-
ous; clamping of the porta hepatis can
produce acute spleen rupture in patients
without chronic portal hypertension.3
Chiappini and associates1 used the chev-
ron incision, whereas we preferred a me-
dian sternolaparotomy in all cases. The
former is optimal to expose right-sided
lesions, which are much more common
because of the IVC location and shorter
length of the renal vein. However, we
encountered left-sided tumors with IVC
extension in 25% of our patients.
Finally, all late deaths in our series were
related to metastatic cancer. Chiappini and
associates1 reported that 4 of 13 patients
had distant metastases identified before the
operation. Although obstructive symptoms
may be successfully palliated, we believe
that an operation is contraindicated in such
cases. This does not apply to patients who
require associated pulmonary tumor embo-
lectomy.
Marco Pocar, MD, PhD
Francesco Donatelli, MD
Cattedra di Cardiochirurgia
Universita` degli Studi di Milano
Milan, Italy
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Reply to the Editor:
My colleagues and I thank Pocar and Do-
natelli for their appreciation of our article.
None of our patients showed a low preop-
erative ejection fraction like that seen in 2
patients in their study, and we agree that
left ventricular dysfunction may represent a
relative contraindication for operation with
prolonged circulatory support and deep hy-
pothermic techniques. Early postoperative
outcomes in our study population confirm
that cardiopulmonary bypass with deep hy-
pothermic circulatory arrest carries reduced
risks of warm renal and hepatic ischemia.
As do Pocar and Donatelli, we prefer to
perform atriotomy before cavotomy to gain
open distal access and reduce embolic
risks. In our experience the chevron inci-
sion is the best surgical approach, provid-
ing the safest and widest exposure for re-
moving these tumors and tumor thrombus.
We agree with Pocar and Donatelli re-
garding the contraindication of surgery for
patients with diffuse metastatic cancer be-
cause of the high risk/benefit ratio.
Bruno Chiappini, MD
Department of Cardiovascular Surgery
Policlinico S. Orsola-Malpighi
University of Bologna
Bologna, Italy
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Partial left ventriculectomy in
patients with neoplasms and severe
heart failure who are not candidates
for cardiac transplantation
To the Editor:
I read the article of Casarotto and col-
leagues1 with great interest. The article de-
scribed a patient with Castleman disease
who was treated with chemotherapy, lead-
ing to a dilated cardiomyopathy. Because
of the neoplasm, cardiac transplantation
was contraindicated. Because of a progre-
dient severe heart failure, the patient had to
be supported with a Novacor (World Heart
Corporation, Ottawa, Ontario, Canada) left
ventricular assist device (LVAD). After a
total of 1512 days, the patient had no signs
of a relapse of Castleman disease and un-
derwent orthotopic heart transplantation.
The number of patients with severe
heart failure after chemotherapy for neo-
plasms should not be underestimated: from
1990 to 1996, cardiac transplantation was
performed in 89 selected patients in the
United States for this indication.2 The num-
ber of patients in whom cardiac transplanta-
tion cannot be performed because there is no
proof of cure of the neoplasm is probably
much higher. Therefore these patients are not
so rare as might be supposed, and alternative
treatment concepts are necessary.
Recently, I introduced a canine model
for research on partial left ventriculectomy
(PLV).3,4 Heart failure was induced by in-
tracoronary doxorubicin administration,
leading to a dilated cardiomyopathy with
histologic myocardial changes similar to
those described by Casarotto and col-
leagues.1 PLV was performed by resecting
the interpapillary segment of the left ven-
tricle (group 2). Measurement of hemody-
namic and echocardiographic parameters
demonstrated an improvement of left ven-
tricular function relative to a control group
without PLV (group 1; Table 1).
PLV thus may also work in chemother-
apy-induced heart failure, and I propose it
as an alternative treatment option. PLV has
some advantages relative to LVAD implan-
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tation. Well-known drive line or device
pocket infections, as well as mechanical fail-
ures (also described by Casarotto and col-
leagues1), are not possible with PLV. Anti-
coagulation treatment is avoided, reducing
the risk of bleeding complications. Thrombo-
embolic events caused by clot formation
within the LVAD are also avoided. Further-
more, PLV is much less invasive than LVAD
implantation, and quality of life is enhanced
by avoiding a transcutaneous drive line and
dependence on a mechanical device. Regard-
ing the economic aspect, costs for PLV are
much lower than for LVAD implantation,
and PLV can be performed in many more
hospitals than can LVAD implantation,
which is restricted to specialized centers.
I congratulate Casarotto and col-
leagues1 on their successful management
of this difficult case. However, I encourage
cardiac surgeons to take alternative treat-
ment options such as PLV into consider-
ation in such challenging cases.
Stefan Christiansen, MD
Department of Cardiothoracic Surgery
University of Aachen
Aachen, Germany
References
1. Casarotto D, Bottio T, Gambino A, Testolin
L, Gerosa G. The last to die is hope: pro-
longed mechanical circulatory support with a
Novacor left ventricular assist device as a
bridge to transplantation. J Thorac Cardio-
vasc Surg. 2003;125:417-8.
2. Shah HR, Vaynblat M, Ramdev G, Cunning-
ham JN, Chiavarelli M. Experimental cardio-
myopathy as a model of chronic heart failure.
J Invest Surg. 1997;10:387-96.
3. Christiansen S, Redmann K, Scheld HH, Jahn
UR, Stypmann J, Fobker M, et al. Adriamy-
cin-induced cardiomyopathy in the ca-
nine—an appropriate model for research on
partial left ventriculectomy? J Heart Lung
Transplant. 2002;21:783-90.
4. Christiansen S, Stypmann J, Jahn UR, Red-
mann K, Fobker M, Gruber AD, et al. Partial
left ventriculectomy in the modified adriamy-
cin-induced cardiomyopathy in the dog.
J Heart Lung Transplant. 2003;22:301-8.
doi:10.1016/j.jtcvs.2003.06.014
Aortic insufficiency in patients with
Marfan syndrome: A surgical
dilemma
To the Editor:
The excellent article by de Oliveira and
colleagues1 and the related editorial by
Miller2 are vital reading for all those in-
volved in the management of patients with
Marfan syndrome (MFS). In their article,
de Oliveira and colleagues1 reported the
results of surgery for aortic root aneurysm
in patients with MFS. Sixty-one of these
patients underwent aortic valve–sparing
operations, with reimplantation of the aor-
tic valve in 39 patients and remodeling of
the aortic root in 22. Patient age ranged
between 12 and 59 years. Freedom from
reoperation at 10 years was 100%, but only
2 patients had a full 10-year follow-up.
Twenty-one percent of patients required re-
exploration for bleeding (only 3% in the re-
implantation group). Perhaps the most signif-
icant finding was that 25% of patients had
more than 2 aortic insufficiency during the
follow-up period. Thus if aortic insufficiency
continues to progress through a longer fol-
low-up period, reoperation will be necessary
in a significant number of patients.
Histologic evaluation of the leaflets of
the aortic valve has demonstrated four dif-
ferent layers. The subendocardial ventricu-
lar layer is composed of elastic fibers ori-
ented in various directions.3 The
noncoaptational parts of the aortic leaflets
are composed of an elastic grid reinforced
with collagen fibers and bundles. The re-
maining layers have irregular amounts of
arbitrarily oriented elastic fibers and colla-
gen fibers.3 MFS is caused in part by mu-
tations within the gene for fibrillin 1, which
is the main protein of the microfibril net-
work. Microfibrils play a crucial role in the
trophicity and function of elastic tissue.4 In
MFS, these mutations lead to the formation
of thoracic aortic aneurysms5 and appear to
be related to proteolytic degradation.6 If
the progression of aortic insufficiency in de
Oliveira and colleagues’ series1 is due to
causes inherent in the surgical technique,
this problem could probably by prevented by
modifications in the surgical technique.
David has already modified this technique
several times,2 and all these modifications are
included in the cases in this study. If aortic
insufficiency is due to a structural deficiency
of the native aortic leaflets, however, then all
patients are at a potentially high risk for re-
operation.
Kon and associates7 have recently re-
ported the results of root replacement with
the Freestyle bioprosthesis (Medtronic, Inc,
Minneapolis, Minn) in 104 consecutive pa-
tients with multiple etiologies of aortic
valve disease who took part in the world-
wide study for submission to the Food and
Drug Administration for premarket ap-
proval of this valve. Patient age ranged
from 48 to 87 years. Freedom from reop-
eration was 100% at 8 years, with no struc-
tural valve deterioration. More signifi-
TABLE 1. Hemodynamic and echocardiographic parameters before and after
doxorubicin chemotherapy with (group 2) or without (group 1) PLV
Before After 6 wk later
LVEDV (mL)
Group 1 55.7 12.2 65.5 5.7 67.3 5.6
Group 2 54.6 5.0 66.4 4.6 60.2 4.5
LVESV (mL)
Group 1 22.0 6.7 40.6 8.2 46.6 5.3*
Group 2 23.0 2.7 41.5 6.9 34.3 4.9*
Cardiac
output
(L/min)
Group 1 4.0 0.3 3.3 0.1 3.0 0.2*
Group 2 3.9 0.3 3.1 0.2 3.3 0.1*
Ejection fraction (%)
Group 1 61.1 5.1 37.7 5.7 30.5 5.8
Group 2 57.7 9.0 37.2 12.2 42.6 10.5
Oxygen delivery (mL/min)
Group 1 1130 170 790 65 728 111
Group 2 1153 155 765 53 820 95
Oxygen extraction
Group 1 0.12 0.01 0.24 0.01 0.32 0.01*
Group 2 0.13 0.01 0.26 0.01 0.26 0.01*
LVEDV, Left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.
*P  .05.
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